Trinity Biotech PLC (TRIB)
1.69
0.00 (0.00%)
USD |
NASDAQ |
Nov 04, 16:00
1.69
0.00 (0.00%)
After-Hours: 20:00
Trinity Biotech Net Income (Quarterly): -6.757M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -6.757M |
| March 31, 2024 | -3.317M |
| December 31, 2023 | -5.501M |
| September 30, 2023 | -6.721M |
| June 30, 2023 | -5.988M |
| March 31, 2023 | -5.809M |
| December 31, 2022 | -10.08M |
| September 30, 2022 | -8.945M |
| June 30, 2022 | -9.706M |
| March 31, 2022 | -12.28M |
| December 31, 2021 | -1.265M |
| September 30, 2021 | 1.321M |
| June 30, 2021 | -0.783M |
| March 31, 2021 | 1.602M |
| December 31, 2020 | -10.02M |
| September 30, 2020 | 7.325M |
| June 30, 2020 | -1.467M |
| March 31, 2020 | -2.222M |
| December 31, 2019 | -23.32M |
| September 30, 2019 | 0.025M |
| June 30, 2019 | -5.405M |
| March 31, 2019 | -0.211M |
| December 31, 2018 | -23.96M |
| September 30, 2018 | 0.896M |
| June 30, 2018 | 0.594M |
| Date | Value |
|---|---|
| March 31, 2018 | 0.378M |
| December 31, 2017 | -42.86M |
| September 30, 2017 | 0.445M |
| June 30, 2017 | 0.902M |
| March 31, 2017 | 1.246M |
| December 31, 2016 | -100.87M |
| September 30, 2016 | -0.517M |
| June 30, 2016 | 2.104M |
| March 31, 2016 | -1.347M |
| December 31, 2015 | 2.826M |
| September 30, 2015 | 12.26M |
| June 30, 2015 | 2.694M |
| March 31, 2015 | 4.008M |
| December 31, 2014 | 4.125M |
| September 30, 2014 | 4.361M |
| June 30, 2014 | 4.315M |
| March 31, 2014 | 4.413M |
| December 31, 2013 | 4.639M |
| September 30, 2013 | -2.989M |
| June 30, 2013 | 3.828M |
| March 31, 2013 | 4.168M |
| December 31, 2012 | 4.469M |
| September 30, 2012 | 4.46M |
| June 30, 2012 | 4.302M |
| March 31, 2012 | 4.11M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-23.32M
Minimum
Dec 2019
7.325M
Maximum
Sep 2020
-5.470M
Average
-5.809M
Median
Mar 2023
Net Income (Quarterly) Benchmarks
| Amarin Corp PLC | -25.13M |
| DBV Technologies SA | -33.12M |
| Ascendis Pharma AS | -117.77M |
| Cellectis SA | -25.27M |
| Adaptimmune Therapeutics PLC | 69.52M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 15.84M |
| Total Expenses (Quarterly) | 17.51M |
| EPS Diluted (Quarterly) | -0.726 |
| Enterprise Value | 91.66M |
| Gross Profit Margin (Quarterly) | 36.19% |
| Profit Margin (Quarterly) | -42.65% |
| Earnings Yield | -159.5% |
| Normalized Earnings Yield | -153.85 |